.png)
Background: Major depressive disorder is a debilitating mental condition that causes severe disability leading to a high fatality rate. No valid blood-based biomarkers for major depressive disorder are currently available. The purpose of this research is to investigate gene biomarkers and pathways that may be linked to major depressive disorder pathogenesis.
Methods: Two microarray databases were retrieved from Gene Expression Omnibus for screening of candidate differentially expressed genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed followed by protein–protein interaction network of differentially expressed genes.
Results: About 1181 differentially expressed genes were identified from the microarray databases. Gene Ontology analyses indicated that these differentially expressed genes were significantly enriched in mRNA splicing via spliceosome, neutrophil degranulation, peptide antigen assembly with MHC class II protein complex, and immunoglobulin production-mediated immune response. The most enriched Kyoto Encyclopedia of Genes and Genomes pathway terms of the 10 significant were Hematopoietic cell lineage. About 20 genes were identified as hub genes after pathway analyses, mostly involved in colorectal cancer and the composition of ribosomes and protein processing, including KRAS, CD86, RPL9, RPL3, and RPL18.
Conclusion: New candidate genes have been identified using bioinformatic approaches that suggest their involvement in the pathogenesis of major depressive disorder and serve as potential genetic diagnostic markers as well as new therapeutic targets.
Cite this article as: Li J, Ma Q, Ai M. Identification and analyses of crucial genes associated with pathogenesis of major depressive disorder. Psychiatry Clin Psychopharmacol. 2023;33(4):264-271.